Today is World Lymphoma Day. Lymphoma (affecting lymphocytes) is one of the three main types of blood cancer, along with leukemia (blood and bone marrow) and myeloma (plasma cells). There are two categories of lymphoma: Hodgkin (HL) and non-Hodgkin (NHL).
NHL is the 15th most deadly cancer in Mexican women and 12th in Mexican men, killing over 2,000 Mexicans in 2014. HL ranks close to the bottom of most deadly cancers in Mexico, killing less than 1,000 in the same year.
The five year relative survival rate for Hodgkin lymphoma is 86 percent across all patients, and 71 for non-Hodgkin lymphoma. Chemotherapy is an option for some cases of HL and NHL, and research for both variants into stem cell treatments and CAR T cells is ongoing.
Drugs undergoing trials to treat NHL include phosphatidyl-inositide 3 kinase (PI3K) inhibitors, BCL-2 inhibitors, janus kinase (JAK) inhibitors and tyrosine kinase inhibitors. Other phosphatidyl-inositide 3 kinase (PI3K) inhibitors, janus kinase (JAK) inhibitors, mTOR inhibitors and histone deacetylase (HDAC) inhibitors are being researched to treat HL.
In Mexico, Bristol-Myers Squibb’s drug nivolumab recently received extended authorization to treat HL, head and neck cancer and metastatic melanoma, in addition to the previously authorized lung, kidney and skin cancer.